Pharmaceutical practice of one case of severe liver injury caused by enoxaparin due to renal injury caused by iodomepral

Published on Jul. 29, 2023Total Views: 2021 times Total Downloads: 1273 times Download Mobile

Author: Qiang YANG ^# Shuang LIU ^# Jia-Li MI  Peng ZHANG

Affiliation: Department of Pharmacy, Suining Central Hospital, Suining 629000, Sichuan Province, China #Co-first author: Qiang YANG and Shuang LIU

Keywords: Iodomepral Renal injury Enoxaparin Liver injury Pharmaceutical care

DOI: 10.19960/j.issn.1005-0698.202307014

Reference: Qiang YANG, Shuang LIU, Jia-Li MI, Peng ZHANG.Pharmaceutical practice of one case of severe liver injury caused by enoxaparin due to renal injury caused by iodomepral[J].Yaowu Liuxingbingxue Zazhi,2023, 32(7):836-840.DOI: 10.19960/j.issn.1005-0698.202307014.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A 67-year-old man with lung adenocarcinoma complicated with heart failure developed acute kidney injury (Scr 149 μmol·L^-1, BUN 13.23 mmol·L^-1, UA 439 μmol·L^-1) and severe liver injury (ALT 592 U·L^-1, AST 782 U·L^-1, γ-GGT 121 U·L^-1). By medication analysis, the pharmacist considered that iodomepral most probably induced acute renal injury, which then led to the accumulation of enoxaparin in the body and caused severe liver injury. The pharmacist advised doctor to monitor the changes of renal function, withdrawal enoxaparin sodium and discontinue almonertinib mesylate. Then, the liver and renal functions returned to normal. This case indicates that contrast induced nephropathy may occur in patients with high-risk after the use of contrast agents, and may further lead to accumulation of other medication. Pharmacists should provide pharmaceutical mon-itoring, medication analysis and sufficient clinical evaluation to assist doctors in adjusting treatment scheme for such patients.

Full-text

Please download the PDF version to read the full text: download

References

1.Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency[J]. Am J Kidney Dis, 2002, 39(5): 930-936.DOI: 10.1053/ajkd.2002.32766.

2.Tao SM, Wichmann JL, Schoepf UJ, et al. Contrast-induced nephropathy in CT: incidence, risk factors and strategies for prevention[J]. Eur Radiol, 2016, 26(9): 3310-3318. DOI: 10.1007/s00330-015-4155-8.

3.中华医学会放射学分会对比剂安全使用工作组. 碘对比剂使用指南(第2版)[J]. 中华医学杂志, 2014, 94(43): 3363-3369. DOI: 10.3760/cma.j.issn.0376-2491.2014.43.003.

4.van de Wal RM, Asselbergs FW, Plokker HW, et al. High prevalence of microalbuminuria in chronic heart failure patients[J]. J Card Fail, 2005, 11(8): 602-606. DOI: 10.1016/j.cardfail.2005.05.007.

5.Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition[J]. Circula-tion, 2016, 133(11): 1115-1124. DOI: 10.1161/CIRCULATIONAHA.115.018622.

6.刘萧, 洪葵. 心力衰竭治疗的新策略: 血管紧张素受体脑啡肽酶双重抑制剂[J]. 中华心血管病杂志, 2015, 43(12): 1025-1027. [Liu X, Hong K. A new strategy for the treatment of heart failure: dual inhibitors of angio-tensin receptor enkephalin enzyme[J]. Chinese Journal of Cardiology, 2015, 43(12): 1025-1027.] DOI: 10.3760/cma.j.issn.0253-3758.2015.12.004.

7.陈琪莹, 李毅敏, 陈文发. 基于FAERS对沙库巴曲缬沙坦不良反应的分析研究[J]. 中国医院药学杂志, 2021, 41(3): 264-268. [Chen QY, Li YM, Chen WF. Analytical study of adverse reactions of sacubitril/valsartan based on FAERS[J]. Chinese Jour-nal of Hospital Pharmacy, 2021, 41(3): 264-268.] DOI: 10.13286/j.1001-5213.2021.03.06.

8.白婷, 杨蕊, 朱琳, 等. 沙库巴曲缬沙坦钠相关不良反应文献分析[J]. 临床药物治疗杂志, 2022, 20(9): 82-85. [Bai T, Yang R, Zhu L, et al. Literature analysis of adverse reactions associated with sacubitril/valsartan[J]. Clinical Medica-tion Journal, 2022, 20(9): 82-85.] DOI: 10.3969/j.issn.1672-3384.2022.09.016.

9.国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2019, 11(7): 1-78. DOI: 10.12037/YXQY.2019.07-01.

10.Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-184. DOI: 10.1159/000339789.

11.中华医学会临床药学分会, 中国药学会医院药学专业委员会, 中华医学会肾脏病学分会. 碘对比剂诱导的急性肾损伤防治的专家共识[J]. 中华肾脏病杂志, 2022, 38(3): 265-288. DOI: 10.3760/cma.j.cn441217-20210909-00041.

12.国家药品不良反应监测中心. 药品不良反应报告和监测手册[EB/OL]. ( 2012-11-01) [2021-11-19]. http://www.cdradr.org.cn/xzzx/hyzl/hyzl2013nd/201304/t201304265436.Html.

13.张聪, 史琛, 解吉奕, 等. 阿美替尼治疗非小细胞肺癌的研究进展[J].中国医院药学杂志, 2022, 42(15): 1613-1618. [Zhang C, Shi C, Xie JY, et al. Research progress in aumolertinib in the treatment of non-small-cell lung cancer[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(15): 1613-1618.] DOI: 10.13286/j.1001-5213.2022.15.20.

14.Fareed J, Hoppensteadt D, Walenga J. Pharmacodynamic and pharmacokinetic properties of enoxapa-rin: implications for clinical practice[J]. Clin Pharmacokinet, 2003, 42(12): 1043-1057. DOI: 10.2165/00003088-200342120-00003.

15.Shaikh SA, Regal RE. Dosing of enoxaparin in renal impairment[J]. P T, 2017, 42(4): 245-249. https://pubmed.ncbi.nlm.nih.gov/28381917/.

16.Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update[J]. Int J Mol Sci, 2015, 17(1): 14-47. DOI: 10.3390/ijms17010014.

17.刘雅丽, 苏娜, 徐珽. 碘美普尔性肾损伤致头孢他啶蓄积性四肢震颤1例[J]. 药物流行病学杂志, 2021, 30(8): 567-569. [Liu YL, Su N, Xu T. A case of ceftazidime accumulated limb tremor caused by iodomepral renal injury[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(8): 567-569.] DOI: 10.19960/j.cnki.issn1005-0698.2021.08.014.

18.朱珠, 曹运莉, 孙钢, 等. 肝功能不全分级方法概述[J].中国药师，2012, 15(3): 418-421. [Zhu Z, Cao YL, Sun G, et al. Overview of grading methods for liver dysfunction[J]. Chinese Pharmacist, 2012, 15(3): 418-421]. DOI: 10.3969/j.issn.1008-049X.2012.03.053.

19.于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J]. 实用肝脏病杂志, 2017, 20(2): 257-274. [Yu LC, Mao YM, Chen CW. Guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Journal of Practi-cal Hepatology, 2017, 20(2): 257-274.] DOI: 10.3969/j.issn.1672- 5069.2017.02.039.